文章摘要
谭传斌,李 晶,黄三钱,谭平萍,曾 亮.S100A14在乳腺癌不同分子亚型中表达的临床病理研究[J].,2019,19(13):2528-2533
S100A14在乳腺癌不同分子亚型中表达的临床病理研究
Clinicopathological Study of S100A14 Expression in Different Molecular Subtype of Breast Cancer
投稿时间:2018-11-08  修订日期:2018-11-30
DOI:10.13241/j.cnki.pmb.2019.13.029
中文关键词: S100A14  乳腺癌  分子分型  临床病理
英文关键词: S100A14  Breast cancer  molecular typing  Clinicopathology  significance
基金项目:湖南省卫生计生委科研计划项目(B2017097)
作者单位E-mail
谭传斌 常德市第四人民医院病理科 湖南 常德 415000 675848346@qq.com 
李 晶 湖南省肿瘤医院乳腺内科 湖南 长沙410013  
黄三钱 湖南省肿瘤医院病理科 湖南 长沙410013  
谭平萍 湖南省肿瘤医院乳腺内科 湖南 长沙410013  
曾 亮 广州市妇女儿童医疗中心病理科 广东 广州 510623  
摘要点击次数: 15
全文下载次数: 22
中文摘要:
      摘要 目的:探讨S100钙结合蛋白A14(S100A14)在乳腺癌不同分子亚型中的表达及临床病理意义,为确定新的分子分型标志物提供参考依据。方法:254例乳腺癌石蜡组织来源于2013年1月16日至2014年5月22日在中南大学湘雅医学院附属肿瘤医院暨湖南省肿瘤医院进行乳腺癌根治术的患者。应用免疫组织化学方法检测S100A14在乳腺癌组织中的表达,分析其S100A14在不同分子亚型乳腺癌组织中表达及其与患者临床病理指标间的相关性,采用Kaplan-Meier法分析S100A14蛋白表达与乳腺癌患者预后的关系。结果:S100A14在ER+/PR+/HER2+型、ER+/PR+/HER2-型、ER-/PR-/HER2+型、ER-/PR-/HER2-型乳腺癌四种分子亚型中的阳性表达分别为38.5%、47.1%、75.5%、80.0%,以在ER-/PR-/HER2-型中表达最高,在ER+/PR+/HER2+型中表达最低,四组间的阳性表达比较差异有显著统计学意义(P<0.01);S100A14的表达与乳腺癌患者术后肝转移呈正相关(r=0.134,P<0.05),与ER、PR表达均呈负相关(r=-0.353,P<0.01),而与ER+/PR+/HER2+型、ER+/PR+/HER2-型乳腺癌的临床病理特征无显著相关性(P>0.05)。在ER-/PR-/HER2+型乳腺癌中,有腋窝淋巴结转移组患者的S100A14阳性表达率明显高于无腋窝淋巴结转移组,差异有统计学意义(P<0.05);在ER-/PR-/HER2-型中,S100A14表达与术后肺转移呈负相关(r=-0.272, P=0.044)。结论:S100A14在不同分子亚型乳腺癌中表达存在差异,其表达与不同分子类型乳腺癌转移或复发有关,可能作为乳腺癌分子分型的候选标记物。
英文摘要:
      ABSTRACT Objective: Expression and clinicopathological significance of S100 calcium binding protein A14(S100A14) in different molecular subtypes of breast cancer were explored to provide reference for identifying new molecular typing markers. Methods: Breast cancer tissues were taken cases for radical mastectomy patients from January 16, 2013 to 22 May 2014 at the Cancer Hospital Affiliated to the Xiangya Medical College of Central South University & the Cancer Hospital of Hunan province. Using immunohistochemistry to detect the expression of S100A14 in 254 breast cancer tissues, with emphasis on differences expression of the protein in different molecular subtypes of breast carcinoma and its correlation with clinicopathological factors, Kaplan-Meier analysis was applied for the relationship between S100A14 expression and prognosis of patients with breast cancer. Results: The positive expression of S100A14 in four molecular subtypes of ER+/PR+/HER2+, ER+/PR+/HER2-, ER-/PR-/HER2+ and ER-/PR-/HER2- breast cancer was 38.5%, 47.1%, 75.5%, 80%, respectively. The expression of the 4 groups was the highest in the ER-/PR-/HER2- type and the lowest in the ER+/PR+/HER2+ type, and the difference between the 4 groups was significant (x2=32.997, P<0.001). The relationship between S100A14 and clinicopathological characteristics of 254 cases of breast cancer was analyzed. The expression of S100A14 was significantly negatively correlated with the expression of ER and PR (all r=-0.353, P<0.001), and was significantly positively correlated with postoperative recurrence of liver metastasis with breast cancer (r=0.134, P=0.040). There is no significant correlation between the expression of S100A14 and the clinicopathological features of type ER+/PR+/HER2+ and ER+/PR+/HER2- type breast cancer(P>0.05). In ER-/PR-/HER2+ type breast cancer. The positive expression rate of S100A14 in axillary lymph node metastasis group was significantly higher than that without axillary lymph node metastasis group (x2=6.768, P=0.013), and S100A4 expression has a negative correlation with postoperative pulmonary metastasis (r=-0.272, P=0.044). Conclusion: The expression of S100A14 in breast cancer with different molecular subtypes is different, and its high expression is associated with metastasis or recurrence of breast cancer with different molecular types. It may be used as a candidate marker for molecular typing of breast cancer.
查看全文   查看/发表评论  下载PDF阅读器
关闭